EU Approval Delay for Janssen’s Spravato?
Third-Party Intervention Raises EU Approval Timing Question
Executive Summary
The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.
You may also be interested in...
Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
J&J’s Spravato Gets EU Okay For Drug-Resistant Depression
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.
Axsome Soars After Depression Trial Success
Axsome is set to file for approval in the second half of 2020.